ERCC1、XPD、XPC单核苷酸多态性与局部晚期宫颈癌新辅助化疗敏感性的相关性

目的：探讨DNA修复切除修复交叉互补基因1（ERCC1）、人类着色性干皮病D组基因（XPD）、人类着色性干皮病C组基因（XPC）基因多态性与局部晚期宫颈癌（LACC）铂类为基础的新辅助化疗（NACT）敏感性的关系。方法：经病理学确诊的LACC患者114例，所有病例化疗前抽取静脉血并提取DNA，采用聚合酶链式反应-限制性片段长度多态性分析（PCR-RFLP）技术检测单核苷酸多态性（SNPs），比较不同基因型与NACT疗效的关系。结果：携带ERCC1 Asn118Asn C/T基因型的化疗敏感率高于C/C基因型，差异有统计学意义（P＜0.05），携带C/T基因型化疗敏感性比C/C基因型增加4.48倍（OR=4.480；95%CI=1.436～13.976）。携带XPD Lys751Gln A/A基因型化疗敏感性高于A/C基因型，但差异无统计学意义（P＞0.05）。XPC Lys939Gln基因型与化疗敏感性差异无统计学意义（P＞0.05）。结论：ERCC1 Asn118Asn多态性可以预测以铂类为基础的LACC患者化疗疗效。

Association between ERCC1, XPD,XPC polymorphisms and chemosensitivity of platinum-based neoadjuvant chemotherapy in patients with locally advanced cervical cancer

Objective: To investigate whether single-nucleotide polymorphisms of ERCC1, XPD, XPC affected response in locally advanced cervical cancer (LACC) receiving platinum-based neoadjuvant chemotherapy (NACT). Methods: A total of 114 patients who were pathologically diagnosed as cervical carcer treated with platinum-based neoadjuvant chemotherapy were examined for genotyping of ERCC1, XPD and XPC in peripheral blood lymphocytes with the method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RPLF), and than the correlation between different genotypes with NACT curative effect was analized. Results: Variant genotypes of ERCC1 Asn118Asn were significantly associated with /C genetype LACC chemosensitivity (P<0.05). To compare ERCC1 Asn118Asn C/T genetype with ERCC1 Asn118Asn C/C genetype, chemosensitivity increased 4.48 times (odds ratio 4.48; 95%CI: 1.436-13.976; P<0.05). While no significant difference was found between chemotherapy response and SNPs of XPD condon 751 and XPC condon 939 (P>0.05). Conclusion: Our study provides evidence for the predictive role of ERCC1 Asn118Asn on chemotherapy response in LACC patients treated with.